Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.
Offering improved detection for breast cancer in women with dense breasts as well as enhanced diagnosis of invasive lobular cancer, the AI-powered ProFound Detection Version 4.0 software for digital breast tomosynthesis (DBT) has garnered 510(k) clearance from the Food and Drug Administration (FDA).
ProFound Detection Version 4.0 provides a 50 percent improvement for diagnosing breast cancer in women with dense breasts in comparison to the previous version of the software, according to iCAD, the manufacturer of ProFound Detection Version 4.0.
The newly FDA-cleared ProFound Detection Version 4.0 software leverages artificial intelligence (AI) to provide enhanced detection of breast cancer in women with dense breasts as well as invasive lobular cancer on digital breast tomosynthesis (DBT) in comparison to a previous version of the AI software. (Image courtesty of iCAD.)
In contrast to the third version of the software, iCAD said ProFound Detection Version 4.0 also offers a 60 percent improvement in diagnosis of invasive lobular cancer, a 38 percent improvement in detecting cancer smaller than 1 cm and a 21 percent improvement in identifying invasive breast cancer.
“ProFound Detection Version 4.0 will dramatically improve breast cancer detection,” noted Chirag Parghi, M.D., M.B.A., the chief medical officer at Solis Mammography. “The newest version’s ability to detect subtle invasive cancers, especially within dense breast tissue, addresses one of the biggest challenges in breast imaging today.”
Noting the software’s potential for reducing false positives, iCAD said ProFound Detection Version 4.0 offers a 20 percent reduction in marks related to vascular calcification and a 51 percent reduction in marks related to non-vascular calcification. The software, which will be showcased at the upcoming Radiological Society of North America (RSNA) 2024 Annual Meeting, also enables radiologists to include a prior DBT examination into the AI analysis, according to iCAD.
Recent Videos
Related Content
Improving Adherence to Best Practices for Incidental Abdominal Aortic Aneurysms on CT and MRI
November 5th 2024Article
In recent interviews, Eric Rohren, M.D., and Krishna Nallamshetty, M.D., discuss the potential of abdominal aortic aneurysms (AAAs) to progress into life-threatening consequences and an emerging AI-powered tool that may bolster adherence to best practice recommendations in radiology reporting of incidental AAA findings on CT and MRI.
Can MRI-Based AI Enhance Pre-Op Prediction of Tumor Deposits in Patients with Rectal Cancer?
October 31st 2024Article
For patients with rectal cancer, an emerging nomogram that combines deep learning and clinical factors had greater than 16 percent and 23 percent increases in accuracy and specificity, respectively, for pre-op prediction of tumor deposits in comparison to clinical factors alone.
Study: AI Bolsters Sensitivity for Pneumothorax on CXR and Significantly Reduces Reporting Time
October 30th 2024Article
For clinically actionable pneumothorax, an artificial intelligence algorithm demonstrated a 93 percent AUC and a 96 percent specificity rate in a study involving chest X-rays from over 27,000 adults.
